PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30497069-6 2018 HMGB1 activated p38 mitogen-activated protein kinase (p38 MAPK) and ADAM17, while HMGB1-induced ADAM17 activation was inhibited by SB203580, a p38 MAPK inhibitor. SB 203580 131-139 high mobility group box 1 Homo sapiens 82-87 30497069-7 2018 HMGB1-induced ectodomain shedding of RAGE and TLR4 was prevented by siRNA depletion of ADAM17 as well as TAPI-2, an inhibitor of ADAM family, and SB203580. SB 203580 146-154 high mobility group box 1 Homo sapiens 0-5 29719300-12 2018 Moreover, HMGB1 activated p38/GSK3beta/Snail signaling pathway and treatment with p38 inhibitor SB203580 abolished its biological effects. SB 203580 96-104 high mobility group box 1 Homo sapiens 10-15 26408615-1 2015 OBJECTIVE: To determine the effect of p38 MAPK inhibitor (SB203580) on TNF-alpha -induced high mobility group protein B1 (HMGB1) expression in microglial cells. SB 203580 58-66 high mobility group box 1 Homo sapiens 90-120 26408615-1 2015 OBJECTIVE: To determine the effect of p38 MAPK inhibitor (SB203580) on TNF-alpha -induced high mobility group protein B1 (HMGB1) expression in microglial cells. SB 203580 58-66 high mobility group box 1 Homo sapiens 122-127 26408615-5 2015 The TNF-alpha-induced HMGB1 protein and mRNA expression was suppressed by SB203580. SB 203580 74-82 high mobility group box 1 Homo sapiens 22-27 23697559-4 2013 The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively. SB 203580 262-270 high mobility group box 1 Homo sapiens 180-185 23697559-4 2013 The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively. SB 203580 262-270 high mobility group box 1 Homo sapiens 394-399 23697559-5 2013 HMGB1-induced activity of ERK1/2 and p38 was not fully inhibited in the presence of U0126 or SB203580. SB 203580 93-101 high mobility group box 1 Homo sapiens 0-5 23628898-7 2013 One of the mechanisms underlying these activating effects of ICs on human endothelial cells involves cell signaling by high-mobility group box 1 protein (HMGB1)-RAGE axis, as these effects can be partially blocked by HMGB1 A-box, soluble RAGE (sRAGE), SB203580, PD98059, Bay 117082 (P<0.05) and co-treatment with these agents (P<0.05). SB 203580 252-260 high mobility group box 1 Homo sapiens 119-144 23628898-7 2013 One of the mechanisms underlying these activating effects of ICs on human endothelial cells involves cell signaling by high-mobility group box 1 protein (HMGB1)-RAGE axis, as these effects can be partially blocked by HMGB1 A-box, soluble RAGE (sRAGE), SB203580, PD98059, Bay 117082 (P<0.05) and co-treatment with these agents (P<0.05). SB 203580 252-260 high mobility group box 1 Homo sapiens 154-159 23333393-4 2013 The inhibitory effect of berberine on LPS-stimulated NO and HMGB1 release was reversed by siRNA-Nrf2, SB203580 (p38 MAPK inhibitor) and zinc protoporphyrin (ZnPP; HO-1 inhibitor) within macrophages. SB 203580 102-110 high mobility group box 1 Homo sapiens 60-65 24302816-7 2013 Furthermore, both NF- kappa B inhibitor Bay11-7085 and p38 inhibitor SB203580 significantly suppressed the enhanced production of IL-6 and MMPs induced by HMGB1-LPS. SB 203580 69-77 high mobility group box 1 Homo sapiens 155-160 22363140-9 2012 HMGB1-induced caspase 3 activation was significantly attenuated by the p38 inhibitor SB203580. SB 203580 85-93 high mobility group box 1 Homo sapiens 0-5 21116767-8 2011 A series of RAGE and HMGB1 co-immunoprecipitation experiments in the presence of SB203580 and PD98059 (p38 MAPK and ERK inhibitors, respectively) demonstrated that RAGE-p38 MAPK and RAGE-ERK pathway might underlie extracellular HMGB1-mediated neuronal apoptosis. SB 203580 81-89 high mobility group box 1 Homo sapiens 21-26 18949384-7 2008 The p38MAPK inhibitor SB203580 and the 5-HT1B antagonist GR55526 markedly inhibited HMGB1 release from 5-HT-stimulated HUVECs. SB 203580 22-30 high mobility group box 1 Homo sapiens 84-89 19726280-8 2009 This synergistic effect was significantly inhibited by pretreatment with MAPK signaling kinases inhibitors, especially the p38 MAP kinase inhibitor SB203580, and the cocktail of MAP kinase inhibitors almost totally blocked the expression of these chemokines in HUVECs treated with HMGB1 and LPS. SB 203580 148-156 high mobility group box 1 Homo sapiens 281-286 17697615-13 2007 Inhibitors specific for the JNK (SP600125), MEK (PD98059), and p38 MAPK (SB203580), abrogated HMGB1-induced TNF-alpha secretion. SB 203580 73-81 high mobility group box 1 Homo sapiens 94-99